Target type: biologicalprocess
The process aimed at the progression of an astrocyte that resides in the forebrain, from initial commitment of the cell to its fate, to the fully functional differentiated cell. An astrocyte is the most abundant type of glial cell. Astrocytes provide support for neurons and regulate the environment in which they function. [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid]
Forebrain astrocyte development is a complex and intricate process that involves a series of tightly regulated molecular and cellular events, ultimately giving rise to these specialized glial cells. Here's a detailed breakdown of the key stages and mechanisms:
**1. Origin and Lineage:**
* Forebrain astrocytes arise primarily from radial glia, multipotent progenitors that also give rise to neurons.
* During early neurogenesis, radial glia undergo asymmetric divisions, generating daughter cells that either remain as radial glia or commit to neuronal fate.
* A subset of radial glia, known as astroglial progenitors, retains the potential to differentiate into astrocytes.
**2. Molecular Regulation:**
* Transcription factors play crucial roles in guiding astrocyte development:
* **Sox9:** Expressed in radial glia and promotes astroglial fate commitment.
* **Nf1a:** Represses neuronal differentiation and promotes astrocyte development.
* **Glial fibrillary acidic protein (GFAP):** A marker for mature astrocytes and involved in astrocyte differentiation and function.
* Signaling pathways like Wnt, Shh, and Notch also contribute to astrocyte development by regulating progenitor proliferation, survival, and differentiation.
**3. Differentiation and Maturation:**
* Astroglial progenitors undergo morphological and molecular changes as they differentiate into mature astrocytes:
* They acquire characteristic stellate morphology with numerous processes that extend and interact with neurons and other glial cells.
* They express specific markers, including GFAP, aldolase C, and glutamine synthetase, indicating their mature astrocytic identity.
* Maturation involves the development of specialized functions, including:
* **Synaptic support:** Astrocytes provide structural and metabolic support for synapses.
* **Neurotransmitter regulation:** They take up and recycle neurotransmitters, helping regulate synaptic transmission.
* **Ion homeostasis:** They maintain ionic balance within the brain by removing excess potassium ions.
* **Blood-brain barrier:** They contribute to the formation and maintenance of the blood-brain barrier, protecting the brain from harmful substances.
**4. Regional Specialization:**
* Within the forebrain, astrocytes exhibit regional heterogeneity, with different subtypes specializing in distinct functions.
* For example, astrocytes in the hippocampus are involved in memory formation, while those in the cortex play roles in cognitive functions.
**5. Plasticity and Response to Injury:**
* Astrocytes are not static cells but are capable of dynamic changes in response to injury, disease, or even aging.
* Following brain injury, astrocytes undergo reactive gliosis, characterized by increased proliferation, hypertrophy, and altered gene expression.
* This reactive response is aimed at protecting the brain from further damage but can also contribute to scar formation and impede neuronal regeneration.
**6. Developmental Disorders:**
* Dysregulation of astrocyte development can lead to neurological disorders:
* Defects in astrocyte differentiation or function may contribute to neurodevelopmental disorders like autism spectrum disorder and intellectual disability.
* Alterations in astrocytic reactive responses may contribute to neurodegenerative diseases like Alzheimer's disease and Parkinson's disease.'"
Protein | Definition | Taxonomy |
---|---|---|
GTPase KRas | A GTPase KRas that is encoded in the genome of human. [PRO:DNx, UniProtKB:P01116] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
benzimidazole | 1H-benzimidazole : The 1H-tautomer of benzimidazole. | benzimidazole; polycyclic heteroarene | |
bisphenol a | 4,4'-isopropylidene diphenol: stimulates proliferative responses and cytokine productions of murine spleen cells and thymus cells in vitro bisphenol : By usage, the methylenediphenols, HOC6H4CH2C6H4OH, commonly p,p-methylenediphenol, and their substitution products (generally derived from condensation of two equivalent amounts of a phenol with an aldehyde or ketone). The term also includes analogues in the the methylene (or substituted methylene) group has been replaced by a heteroatom. bisphenol A : A bisphenol that is 4,4'-methanediyldiphenol in which the methylene hydrogens are replaced by two methyl groups. | bisphenol | endocrine disruptor; environmental contaminant; xenobiotic; xenoestrogen |
bms 214662 | 7-cyano-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine: a farnesyltransferase inhibitor; structure in first source BMS-214662 : A member of the class of benzodiazepines that is 2,3,4,5-tetrahydro-1H-1,4-benzodiazepine substituted by (1H-imidazol-5-yl)methyl, benzyl, (thiophen-2-yl)sulfonyl, and cyano groups at positions 1, 3R, 4 and 7, respectively. It is a potent inhibitor of farnesyltransferase (IC50 = 1.35nM) which was under clinical development for the treatment of solid tumors. | benzenes; benzodiazepine; imidazoles; nitrile; sulfonamide; thiophenes | antineoplastic agent; apoptosis inducer; EC 2.5.1.58 (protein farnesyltransferase) inhibitor |
manumycin | manumycin A : A polyketide with formula C31H38N2O7 initially isolated from Streptomyces parvulus as a result of a random screening program for farnesyl transferase (FTase) inhibitors. It is a natural product that exhibits anticancer and antibiotic properties. manumycin: an NSAID; RN given for (1S-(1alpha,3(2E,4E,6S*),5alpha,5(1E,3E,5E),6alpha))-isomer; a farnesyl protein transferase inhibitor; from Streptomyces parvulus; MF C31-H38-N2-O7; structure given in first source | enamide; epoxide; organic heterobicyclic compound; polyketide; secondary carboxamide; tertiary alcohol | antiatherosclerotic agent; antimicrobial agent; antineoplastic agent; apoptosis inducer; bacterial metabolite; EC 1.8.1.9 (thioredoxin reductase) inhibitor; EC 2.5.1.58 (protein farnesyltransferase) inhibitor; marine metabolite |
sch 54292 | SCH 54292: structure in first source | ||
plx4032 | aromatic ketone; difluorobenzene; monochlorobenzenes; pyrrolopyridine; sulfonamide | antineoplastic agent; B-Raf inhibitor | |
dabrafenib | 1,3-thiazoles; aminopyrimidine; organofluorine compound; sulfonamide | anticoronaviral agent; antineoplastic agent; B-Raf inhibitor | |
ly3009120 | LY3009120 : A member of the class of pyridopyrimidines that is pyrido[2,3-d]pyrimidine substituted by methylamino, 5-{[(3,3-dimethylbutyl)carbamoyl]amino}-4-fluoro-2-methylphenyl, and methyl groups at positions 2, 6 and 7, respectively. It is a potent pan RAF inhibitor which inhibits BRAF(V600E), BRAF(WT) and CRAF(WT) (IC50 = 5.8, 9.1 and 15 nM, respectively). It also inhibits RAF homo- and heterodimers and exhibits anti-cancer properties. LY3009120: a pan-RAF inhibitor; structure in first source | aminotoluene; aromatic amine; biaryl; monofluorobenzenes; phenylureas; pyridopyrimidine; secondary amino compound | antineoplastic agent; apoptosis inducer; autophagy inducer; B-Raf inhibitor; necroptosis inhibitor |
ARS-1620 | ARS-1620 : A qinazoline derivative carrying chloro and fluoro substituents at positions 6 and 8 respectively, a 2-fluoro-6-hydroxyphenyl group at position 7, and a 4-(prop-2-enoyl)piperazin-1-yl group at position 4. A potent, selective, and orally bioavailable covalent KRAS-G12C inhibitor, it inhibits the protein coding gene KRAS (Kirsten rat sarcoma virus) with high potency in cells and animals. ARS-1620: covalent S-IIP G12C inhibitor for targeting of KRAS G12C mutant tumors | quinazolines | antineoplastic agent; antiviral agent; inhibitor |
sotorasib | sotorasib : A pyridopyrimidine that is pyrido[2,3-d]pyrimidin-2(1H)-one substituted by 4-methyl-2-(propan-2-yl)pyridin-3-yl, (2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl, fluoro and 2-fluoro-6-hydroxyphenyl groups at positions 1, 4, 6 and 7, respectively. It is approved for the treatment of patients with non-small cell lung cancer having KRAS(G12C) mutations. sotorasib: a KRAS(G12C) inhibitor | acrylamides; methylpyridines; monofluorobenzenes; N-acylpiperazine; phenols; pyridopyrimidine; tertiary amino compound; tertiary carboxamide | antineoplastic agent |